处方剂量与实时术中定制连接籽源在碘-125前列腺近距离治疗中剂量学优势的关系分析
本研究回顾性分析62例局限期前列腺癌患者,比较单独永久植入(PI,处方剂量160 Gy)与植入联合外照射(PI+EBRT,110 Gy+45 Gy)两种情况下,自由籽源与术中定制连接(IBCL)籽源的剂量学差异。结果显示,在较低处方剂量的PI+EBRT组中,IBCL籽源在植入后剂量学上表现出更优的前列腺D90、V150、均匀指数及尿道D5、D30等参数,而PI组中术中差异在植入后消失。
要点
- 在PI+EBRT(110 Gy+45 Gy)中,IBCL籽源较自由籽源显著改善植入后前列腺D90、V150、HI及尿道D5、D30。
- 在PI单用(160 Gy)中,IBCL与自由籽源的术中剂量学差异在植入后剂量学中未持续存在。
- 两种籽源在PI和PI+EBRT组中的手术时间均无显著差异。
核心结论
- 在较低处方剂量的永久植入联合外照射(如PI+EBRT)中,使用IBCL籽源可获得更大的剂量学优势。
研究设计与样本
- 回顾性分析62例接受经会阴间质近距离治疗的前列腺癌患者,比较自由籽源与IBCL籽源的剂量学参数。
主要发现
- PI组中,IBCL与自由籽源的术中前列腺V100(p=0.003)、D90(p=0.009)及直肠V100(p=0.026)有显著差异,但植入后剂量学无差异。
- PI+EBRT组中,IBCL籽源的术中前列腺V200(p=0.013)、V250(p=0.010)及尿道D30(p=0.038)优于自由籽源。
- PI+EBRT组植入后剂量学中,IBCL籽源的前列腺D90(p=0.004)、V150(p=0.001)、HI(p=0.001)、V200(p=0.001)、V250(p=0.020)及尿道D5(p=0.008)、D30(p=0.003)均更优。
- PI组和PI+EBRT组中,自由籽源与IBCL籽源的手术时间均无显著差异。
关键数值与推荐
- 高危患者39例接受PI(110 Gy)联合EBRT(45 Gy)。
临床怎么用
- 对于接受较低处方剂量永久植入联合外照射的前列腺癌患者,可优先考虑使用IBCL籽源以改善剂量学质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to investigate the differences in the dosimetric advantage of using intraoperatively built custom-linked (IBCL) seeds between permanent iodine-125 (I-125) seed implantation (PI) alone and PI followed by external-beam radiation therapy (EBRT) for prostate cancer. METHODS: We reviewed the records of 62 patients with localized prostate cancer who received transperineal interstitial brachytherapy with I-125 using free seeds or IBCL seeds. Twenty-four low- and intermediate-risk patients underwent PI alone with the prescribed dose of 160 Gy, and 39 high-risk patients underwent PI with 110 Gy, followed by EBRT with 45 Gy (PI + EBRT). Intraoperative and post-implant dosimetric parameters 1 month after implantation were collected and analyzed. RESULTS: The numbers of patients implanted with free seeds and IBCL seeds were 14 (58.3%) and 10 (41.7%), respectively, in the PI group and 25 (65.8%) and 13 (34.2%), respectively, in the PI + EBRT group. In the PI group, although there were significant differences in prostate V100 (p = 0.003) and D90 (p = 0.009) and rectum V100 (p = 0.026) on intraoperative dosimetry, these differences were not found on post-implant dosimetry. In the PI + EBRT group, the dosimetric parameters of IBCL seeds, such as prostate V200 (p = 0.013) and V250 (p = 0.010) and urethra D30 (p = 0.038), were better than those of free seeds on intraoperative dosimetry. Furthermore, even on post-implant dosimetry, prostate D90 (p = 0.004), V150 (p = 0.001), and homogeneity index (HI, p = 0.001), as well as V200 (p = 0.001) and V250 (p = 0.020), and urethra D5 (p = 0.008) as well as D30 (p = 0.003) had a better dosimetric quality in IBCL seeds than in free seeds. There was no significant difference in the operation time between free seeds and IBCL seeds in each PI and PI + EBRT group. CONCLUSIONS: Our results reveal that greater dosimetric benefits could be obtained using IBCL seeds in the case of permanent implantation with a lower prescribed dose, such as PI + EBRT, rather than PI alone.
引用
- Hirose K, Aoki M, Sato M, et al. Analysis of the relationship between prescribed dose and dosimetric advantage of real-time intraoperatively built custom-linked seeds in iodine-125 prostate brachytherapy. Radiat Oncol. 2017. PMID: 29191234. doi:10.1186/s13014-017-0932-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。